Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer
- Conditions
- Advanced Non Small Cell Lung CancerAdvanced Urothelial Carcinoma
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT05318573
- Locations
- 🇺🇸
Cancer and Blood Speciality Clinic, Long Beach, California, United States
🇺🇸Sharp Memorial Hospital (Oncology Clinical Research), San Diego, California, United States
🇺🇸Sibley Memorial Hospital, Washington D.C., District of Columbia, United States
Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT04358549
- Locations
- 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors Including Merkel Cell Carcinoma
- Conditions
- Merkel Cell CarcinomaAdvanced Solid Tumors
- Interventions
- Drug: FF-10850 Topotecan Liposome Injection
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Target Recruit Count
- 96
- Registration Number
- NCT04047251
- Locations
- 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸Dana Farber Cancer Institute (DFCI), Boston, Massachusetts, United States
A Study of FF-10501-01 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome
- Conditions
- Myelodysplastic Syndrome (MDS)
- Interventions
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Registration Number
- NCT03486353
A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors Including Biliary Tract Cancer
- Conditions
- Biliary Tract CancerAdvanced Solid Tumors
- Interventions
- Drug: FF-10832 Gemcitabine Liposome Injection
- First Posted Date
- 2018-02-22
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Fujifilm Pharmaceuticals U.S.A., Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT03440450
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Hoag Memorial Hospital Comprehensive Cancer Center, Newport Beach, California, United States
- Prev
- 1
- 2
- Next
News
FUJIFILM's FF-10832 Receives FDA Orphan Drug Designation for Biliary Tract Cancer Treatment
The FDA has granted orphan drug designation to FF-10832, FUJIFILM's investigational liposomal formulation of gemcitabine, for treating biliary tract cancer.